Assessing Commercial Success at the U.S. Patent Trial and Appeal Board

JOHN JAROSZ
Managing Principal, Analysis Group, Inc., USA

&

ROBERT L. VIGIL
Principal, Analysis Group, Inc., USA

INTRODUCTION
U.S. patents increasingly are challenged on validity grounds through inter partes reviews at the U.S. Patent Trial and Appeal Board (“PTAB” or “board”).1 In fact, from September 2012 through June 30, 2015, there have been over 3,000 inter partes review (“IPR”) petitions filed by petitioners.2 Filings per month have increased from an average of 28 petitions in 2012 to 58 in 2013 to 125 in 2014 to 144 so far in 2015.3

Many patent owners raise a “commercial success” defense in response to such challenges. They argue that the success of products embodying the challenged patent proves that the patented invention must not have been obvious. Had the invention been obvious, the argument goes, the products embodying the patented invention would not have enjoyed the marketplace success that they, in fact, did. If the invention was obvious, someone else would have introduced a product incorporating the patented features earlier.

Patent owners rarely have been successful at the PTAB in invoking this defense. In 82 final written decisions in IPR proceedings (through June 2015) that considered commercial success as a potential defense to patentability, the patent owner prevailed only twice.4 In all other cases, the patent owner failed in proving non-obviousness through a showing of commercial success.

As decades of litigation in U.S. federal district courts have shown, proving commercial success often depends on the effective presentation of economic evidence. Litigants in PTAB proceedings are beginning to learn those lessons; many patent owners are learning the hard way.

This article examines commercial success evaluations at the PTAB. It will show the kinds of economic evidence that are relevant to such evaluations and how such evidence has failed to be used and presented by patent owners arguing commercial success. Much guidance comes directly from PTAB decisions. Other guidance comes from federal district court opinions.

---

1. **BACKGROUND**

   **A. Legal Framework**

   A patent claim is unpatentable under 35 U.S.C. § 103(a) if the differences between the claimed subject matter and the prior art are such that the subject matter, as a whole, would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.\(^5\) The question of obviousness is resolved on the basis of several underlying factual determinations, including 1) the scope and content of the prior art; 2) any differences between the claimed subject matter and the prior art; 3) the level of skill in the art; and 4) secondary considerations.\(^6\)

   Secondary considerations include commercial success, long-felt but unsolved needs, failure of others, unexpected results, copying, licensing, and praise.\(^7\) Secondary considerations are not just a confirmatory part of the obviousness calculus, but constitute independent evidence of non-obviousness.\(^8\) Evidence regarding secondary considerations must be considered as part of all the evidence, not just when the decision maker is in doubt after reviewing the prior art.\(^9\)

   An assessment of commercial success entails a two-part analysis. First, the patent owner must establish that the products that embody the invention have been successful in the marketplace.\(^10\) That is, there must be proof of marketplace success. Second, the patent owner must show that the marketplace success was driven by the advantages of the claimed invention.\(^11\) That is, there must be proof of a causal nexus. The law presumes that an invention would have been commercialized earlier in response to economic incentives if the idea had been obvious to persons skilled in the art.\(^12\) Proof of commercial success overcomes this presumption.

   **B. PTAB Reviews**

   From the PTAB’s inception on September 16, 2012 through June 30, 2015, there were 3,160 IPR petitions challenging one or more patent claims.\(^13\) Of these, 415 have gone to trial and resulted in final written decisions. In 351 of these petitions, the board found some or all of the claims to be unpatentable. In the remaining 64 trials, the board found that no instituted claims were unpatentable. In other words, the patent owner has prevailed against all of the challenged claims in only 15 percent of written decisions.

   Of the cases that reached a final written decision, 82 involved a consideration of commercial success as a potential defense to patentability. The patent owner prevailed in only two of them. In Redline Detection, LLC v. Star Envirotech, Inc., the board found that the petitioner had not demonstrated adequately that the claims at issue were rendered

---


\(^6\) Graham et al. v. John Deere Co. of Kansas City et al., 383 U.S. 1, 17-18 (1966).

\(^7\) See, e.g., KSR, 550 U.S. at 406; In re Soni, 54 F.3d 746 (Fed. Cir. 1995); Graham, 383 U.S. at 17; Leapfrog Enters., Inc. v. Fisher-Price, Inc., 485 F.3d 1157, 1162 (Fed. Cir. 2007).

\(^8\) Leo Pharm. Prods., Ltd. v. Rea, 726 F.3d 1346, 1358 (Fed. Cir. 2013).


\(^10\) In re GPAC Inc., 57 F.3d 1573, 1580 (Fed. Cir. 1995); Demaco Corp. v. F. Von Langsdorff Licensing Ltd., 851 F.2d 1387, 1392 (Fed. Cir. 1988); Crocs, Inc. v. International Trade Com’n, 598 F.3d 1294, 1310-11 (Fed. Cir. 2010).

\(^11\) See, e.g., Merck & Co., Inc. v. Teva Pharms. USA, Inc., 395 F.3d 1364, 1376 (Fed. Cir. 2005); Ormco Corp. v. Align Tech. Inc., 463 F.3d 1299, 1311-12 (Fed. Cir. 2006); In re GPAC Inc., 57 F.3d at 1580 (Fed. Cir. 1995); In re Ben Huang, 100 F.3d 135, 140 (Fed. Cir. 1996).

\(^12\) Merck & Co., Inc. v. Teva Pharmaceuticals USA, Inc., 395 F.3d 1364, 1376-77 (Fed. Cir. 2005).

obvious.\textsuperscript{14} As a result, the board did not deem it necessary to reach the merits of the patent owner’s secondary consideration arguments (including commercial success). In \textit{Intri-Plex Technologies, Inc. et al. v. Saint-Gobain Performance Plastics Rencol Limited}, the board found that the commercial success evidence weighed in favor of non-obviousness of the invention.\textsuperscript{15} It found that the flared tolerance rings at issue “achieved the dominant position in the relevant market” and the petitioners’ own admissions constituted “strong evidence that the commercial success is attributable to customer demand for the patented features.”\textsuperscript{16}

Notwithstanding these two opinions, patent owners have failed in over 95 percent of the written decisions that consider commercial success. Sometimes, it is because of inadequate proof of marketplace success. (In fact, this was cited explicitly in 28 of the decisions.) Sometimes, it is because of inadequate proof of causal nexus. (This was cited explicitly in 80 of the decisions.) Often, it is because of inadequate proof of both.

\section{Proving Commercial Success}

\subsection{Marketplace Success}

The first step in assessing commercial success is evaluating whether the product or products that embody the invention have been successful in the marketplace. Neither the law nor economics provides a clear and clean definition of “success.” A finding of success does not appear to require that the product be the \textit{most} successful product in a given business or at any particular point in time. If that were the case, then very few products would be viewed as successes, and very few patent owners would prevail in a showing of commercial success. “Success” appears to be an inquiry that is subject to a rule of reason.

In the first instance, a commercial success inquiry requires an \textit{identification} of the product or products that embody the patent.\textsuperscript{17} For patents with apparatus claims, such an inquiry can be fairly straightforward. For patents with method claims, such an inquiry can be somewhat more challenging. Though identification of practicing products may seem obvious, it can be, and has been, overlooked by litigants at the PTAB. For example, in \textit{Smith \& Nephew, Inc. v. Convatec Technologies, Inc.}, the board wrote,

\begin{quote}
We have considered the testimony of […], which purports to show that the AQUACEL(R) Ag product line includes the features of claims 1 and 17 of the ‘981 patent. … […] provides no details of the manufacturing process for AQUACEL(R) Ag products as supporting evidence that the products are manufactured using the steps recited in the claims. Upon cross-examination, […] testified that she has no technical knowledge of the patents and could not confirm whether specific products in the AQUACEL(R) Ag line were covered by the claims of the ‘981 patent. […] Considering we have no evidence of the manufacturing process for any of the products in the AQUACEL(R) Ag product line, we have no means to assess whether any of the products are covered by the claims of the ‘981 patent.\textsuperscript{18}
\end{quote}

\begin{flushright}
\textsuperscript{17} Sometimes, these are products sold by the patent owner. Sometimes, these are products sold by the petitioner. Sometimes, these are products sold by third parties.
\textsuperscript{18} Smith \& Nephew, Inc. v. Convatec Technologies, Inc., Case IPR2013-00097, Paper 90 (internal citations omitted). \textit{See also}, The Scotts Company LLC v. Encap, LLC, Case IPR2013-00110, Paper 79; Cardiocom, LLC
\end{flushright}
Determining whether a product practices a particular patent typically is outside the domain of an economist. In both federal district court and at the PTAB, those determinations most often are made by technical experts and/or company personnel who have knowledge and training in the art. Their opinions frequently are presented through filed reports or declarations.

The next step in the marketplace success inquiry is an evaluation of the success of the practicing products in absolute terms. Depending on the product and available data, this is often done by identifying one or more of several financial performance metrics: 1) units sold, 2) volumes shipped, 3) revenues received, 4) profits earned, and 5) prescriptions written. Evidence regarding product success, in absolute terms, can often be obtained from a company’s internal financial records and third party market research reports.

The final, and probably most important, step in the marketplace success inquiry is an evaluation of the success of the practicing products in relative terms. As both the Court of Appeals for the Federal Circuit (“Federal Circuit”) and the PTAB have written repeatedly, merely identifying the level of financial success, without putting that success in context, is insufficient to establish commercial success. Revenues of $10 may be quite significant for a neighborhood lemonade stand. It is much less likely to be significant for Apple, Inc. In Nichia Corporation v. Emcore Corporation, the board wrote,

[…] one of the named inventor of the ‘215 patent, also testifies that ‘the contact of claim 1 was incorporated into hundreds of thousands of LEDs that were sold.’ However, […]’s testimony is not sufficient to support nonobviousness of claim 1, because […]’s testimony does not establish adequately that the sales of hundreds of thousands of LEDs constitutes commercial success when considered in relation to overall market share. […] does not provide any data pertaining to overall market share, and there is no indication that LED sales number represents a substantial quantity in the overall market share.

Patent owners frequently have given inadequate attention to this step of the marketplace success inquiry. In 20 of the PTAB decisions involving a discussion of commercial success, the board wrote that the patent owner did not even attempt to present relative success information. In 11 of the decisions, the board found the presentation to be unpersuasive.

To put financial performance in context, successful patent owners often have identified the set of products with which the patented products compete. Though a formal “relevant market” definition may not be feasible, or even necessary, in a large number of matters,
patent owners (mostly in federal district court) have successfully assessed and identified competing products across relevant geographic areas. Sometimes these competing products include other product lines of the company selling the patented product (such as prior generation products). Other times, these competing products include somewhat similar products sold by third parties.

Evidence about the relevant set of competing products often can be obtained from company market, business, and strategic plans, as well as a company’s external marketing and promotional materials. Relevant evidence also can be found in third party market research reports. In many cases, important observations are obtained through interviews with company marketing personnel and customers purchasing the patented products, and are contained in filed declarations from them.

Once the baseline for comparison is identified, successful patent owners have compared the financial performance of the patented products with that of other products. Typically, this is accomplished by reporting the “market share” captured by the products that embody the claimed invention. Whether that “share” is significant depends upon several factors, including the number of competing products and the timing of a product’s entry into the business. All else equal, the more competitors in the marketplace, the harder it is to break into the business, and the more significant a given market share may be versus what it may appear to be. Further, all else equal, the more established a product’s competitors have been, the more difficult it can be for a new product to enter and gain traction in the business, and the more significant a given market share may be versus what it may appear to be.

B. Causal Nexus

The second step in evaluating commercial success is assessing whether there is a causal nexus between the marketplace success of the products embodying the patent and the advantages of the claimed invention. Neither the law nor economics provides a clear and clean definition of “causal nexus.” A finding of causal nexus does not appear to require that the product be the only reason for a product’s success. Not only is that rarely, if ever, the case, but very few patent owners would prevail in a showing of commercial success if this was required. “Causal nexus” appears to be an inquiry that is subject to a rule of reason.

In the first instance, a causal nexus inquiry typically requires an identification of the specific features/advantages enabled by the invention. Specifically, successful patent owners show how the features/advantages of the patent extend beyond that which was taught in the prior art. In some situations, the features/advantages are co-extensive with the product itself. In most situations, that is not the case.

Determining the features/advantages of the patent is not something that an economist can do alone. Technical experts and/or company personnel who have knowledge and training in the art can be quite useful in undertaking an examination of the claims of the patent and comparing those claims with the prior art. Their opinions are often best presented through filed reports or declarations.

An economist can be useful in translating those technical features/advantages into marketplace features/advantages. That is, though most purchasers often will have little knowledge about or interest in technical product features (including those covered by a

---

patented invention), economic testimony can be useful in determining whether any of the technical features/advantages result in attributes that purchasers care about (such as ease of use, product weight, storage capability, or safety).

Evaluation of causal nexus also requires an assessment of the relative importance to the marketplace of the patent’s features/advantages. Successful patent owners have shown (mostly in federal district court) that these features/advantages made significant contributions toward increased sales, higher prices, or lower costs for products that have embodied the patented technology. In so doing, these patent owners have shown that the patent led to higher profits than the patent owner otherwise would have realized without the patent.

In 5 of the PTAB decisions, the board wrote that the patent owner did not even attempt to identify the advantages of the patent at issue. In 14 of the PTAB decisions, the board wrote that the patent owner did not even attempt to show a causal nexus. And in 66 of the decisions, the board found the presentation of causal nexus to be unpersuasive.

The commercial success of any product usually depends on contributions from a whole host of sources. Some of those sources are features and capabilities of the product itself. Others are non-product features, such as product pricing, promotional activities, and manufacturer brand name and reputation. Establishing causal nexus entails an assessment of the relative significance of the features/advantages enabled by the patent to the success of the patented product, separate from all of the other contributors of value.

Identifying the contribution of broad features generally related to the patent often is not enough. That is, there is a need to assess the specific benefits flowing from the specific

---

23 According to the Federal Circuit, “[commercial] success is relevant in the obviousness context only if there is proof that the sales were a direct result of the unique characteristics of the claimed invention – as opposed to the economic and commercial factors unrelated to the quality of the patented subject matter.” In re Ben Huang, 100 F.3d at 140.

24 See, e.g., Tokai Corp., v. Easton Enters., 632 F.3d 1358 (Fed. Cir. 2011).

claimed invention. Suppose that the benefit of a given patent is that it improves the processor speed of a laptop computer. If there are other technologies that also increase processor speed, it is important to identify how much of the speed improvements seen in the product are due to the patent at issue as opposed to the other technologies. It is the contribution of the incremental speed improvement enabled by the patent that is relevant to the commercial success inquiry.

Moreover, and important in a number of PTAB decisions, is the consideration of the other features and capabilities of the product, as well as the non-product characteristics of the manufacturer. Perhaps setting the bar somewhat higher than it has been set in many federal district court cases, the PTAB often has found it necessary for the patent owner to show that the product’s success is not largely owing to these other (often commercial and economic) factors. For example, the board, in *Kyocera Corporation et al. v. Softview LLC*, wrote,

> Although Patent Owner cites comments lauding the Internet browsing capabilities of the iPhone and Android devices, including a statement made in the Wall Street Journal that the iPhone's game changing feature is its Safari browser, the iPhone's implementation of the Safari browser was just one of its many features. Patent Owner does not address the numerous other features cited as important to the iPhone device, including its use as a phone, Apple's representation that the iPhone is "the best iPod [media player] we ever made," and its e-mail capability. Patent Owner also has not established that the subject matter of the '926 claims, rather than Apple's extensive distribution network and marketing presence are the reason the iPhone and similar devices have been a success. The same is true of Android based devices. In contrast to the declaration of […], a computer science expert with knowledge of computer technologies, Petitioner's expert […], an expert on marketing and consumer behavior, states that the success of such devices can be attributed to numerous factors, including product, promotion, price, and place, and that the web browser in the iPhone was just one of the several important features contributing to its success. Thus, the objective indicia cited by Patent Owner do not overcome the case of obviousness established by Petitioner by a preponderance of the evidence.26

Evidence about the relative importance of product features can be obtained from a number of sources, including the company’s market, business, and strategic plans, as well as the company’s external marketing and promotional materials. This evidence also is contained in third party market research reports and news articles. Important observations often are obtained through interviews with company marketing personnel and customers, and contained in filed declarations from them. Finally, statements and surveys from customers and potential customers can also be quite useful.

These types of evidence do not always provide direct evidence of the relative importance of a particular patent. That is especially true in situations involving assessments of multi-faceted products, like smartphones. It is less true in simpler product settings, like those involving pharmaceuticals. Nonetheless, economic testimony can and should weave

---

together the technical and marketplace information to draw supportable inferences about the relative significance of the patented invention. Sometimes those inferences can be bolstered by evidence gathered from other secondary considerations, such as industry praise, licenses, and copying, some of which is patent-specific. At other times, those inferences can be bolstered by consideration of revealed preferences. That is, a potential infringer’s actions to enter a particular business, though not dispositive, may provide some evidence as to the likely commercial success of both the product and the patent.

3. CONCLUSION

The number of IPR reviews requested at the PTAB is significant and increasing. One part of the response offered by many patent owners to IPR petitions challenging the validity of their patents involves a commercial success defense. This defense argues that the success of products embodying the challenged patents proves that the patented inventions must not have been obvious. At the PTAB, however, patent owners rarely have succeeded with this defense.

There is much room for improvement in the evaluation and presentation of commercial success evidence at the PTAB, with many lessons to be learned from U.S. federal district court cases. In short, products that practice the patent must be shown to be marketplace successes in both absolute and relative terms. And the success must be shown to be caused, in large part, by the tangible features/advantages taught by the patent. Presumptions of success or causality will not rule the day.

***

John Jarosz, a Managing Principal with Analysis Group and Director of the firm's Washington, D.C. office, is an economist who specializes in applied microeconomics and industrial organization. He has provided strategy consultation across a wide range of industries and delivered expert testimony in hundreds of depositions, trials, and hearings. His focus is on matters involving intellectual property, licensing, commercial damages, and antitrust. A frequent author and lecturer on the economics of intellectual property protection, Mr. Jarosz is the editor of Eckstrom's Licensing in Foreign and Domestic Operations: The Forms and Substance of Licensing, and his articles and papers have been published in the Stanford Technology Law Review, the Federal Circuit Bar Journal, les Nouvelles: Journal of the Licensing Executives Society, the Journal of Business Valuation, and the Journal of the Patent and Trademark Office Society. Among other things, Mr. Jarosz has given presentations at various meetings of the Licensing Executives Society and the Association of University Technology Managers, and has taught classes at Georgetown University Law Center, Columbia Business School, and the U.S. Patent and Trademark Office. Mr. Jarosz holds an M.A. and was a Ph.D. candidate in economics from Washington University in St. Louis; a J.D. from the University of Wisconsin; and a B.A. in economics and organizational communication from Creighton University.

Robert L. Vigil is a Principal of Analysis Group, Inc. Dr. Vigil specializes in the application of economics and finance to complex commercial litigation matters. His work includes the estimation of damages and unjust enrichment in intellectual property and breach of contract cases; the evaluation of patented drug products’ commercial success in connection with generic manufacturers’ Abbreviated New Drug Application submissions to obtain early market entry; and the analysis of issues related to the granting of permanent injunctions, such as irreparable harm and causal nexus. Dr. Vigil has also analyzed issues related to domestic industry, remedy, and bonding on cases before the International Trade Commission. He has served as an expert witness on litigation matters in a variety of industries, including pharmaceuticals, medical devices, consumer products, telecommunications, computer hardware and software, and electronics. In non-litigation
matters, he has assisted clients in valuing intellectual property for sale or license; identifying and evaluating potential partners for licensing, acquisition, or divestiture of assets; and analyzing the impact of generic entry on prices and market shares of brand name pharmaceutical products. Vigil holds a B.A. (Pepperdine University) and a Ph.D. in Economics (University of Maryland).

The authors frequently provide economic analysis and testimony in litigation, arbitration, and regulatory proceedings. This article reflects their current thoughts, not necessarily the thoughts of their firm.

We would like to thank Greg Weiss, Mattie Wheeler, and Katie Lin for their valuable research assistance.

Analysis Group has provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune 500 companies, global health care corporations, and government agencies. Our work is grounded in a collaborative approach that allows us to effectively integrate the best ideas from leading academic and industry experts with our more than 600 professionals. As a result, our clients receive thoughtful, pragmatic solutions to their most challenging business and litigation problems. Through our work in thousands of cases across multiple industries we have become one of the largest economics consulting firms in North America, with 11 offices in the United States, Canada, and China.